SAN DIEGO, Dec. 12, 2016 /PRNewswire/ -- Forge
Therapeutics, Inc. announced today that new preclinical data on its
novel class of antibiotic targeting LpxC for treating infections by
Gram-negative drug resistant bacteria will be presented at the
American Society of Microbiology Conference held in Washington, DC from December 11-14, 2016.
Presentation details:
|
Conference
Title:
|
ASM Conference on
Antibacterial Development
|
|
Poster
presentation:
|
Monday, December 12
from 7:00pm to 8:30pm
|
|
Poster
title:
|
#35 Antimicrobial
activity of non-hydroxamate LpxC inhibitors
|
|
Conference
location:
|
Omni Shoreham
Hotel
2500 Calvert Street, NM,
Washington, DC 20008
|
Conference website:
http://conferences.asm.org/index.php/upcoming-conferences/asm-conference-on-antibacterial-development
About LpxC
Drug resistant Gram-negative bacteria are
regarded as an extremely dangerous public health threat, therefore,
novel antibiotics targeting Gram-negative bacteria are desperately
needed. LpxC is a highly sought after target only found in
Gram-negative bacteria. Forge has discovered novel small
molecule inhibitors of LpxC that are potent in vitro,
efficacious and tolerated in vivo, and effective against
drug resistance mechanisms including mcr-1, KPC, and
NDM.
About Forge Therapeutics, Inc.
Forge Therapeutics,
Inc. ("Forge") is a biotechnology start-up that leverages its novel
chemistry platform to develop small molecule inhibitors to target
metalloproteins. Metalloproteins are proteins that
require metal ions for their biological function and make up over
1/3 of the proteins in the human body. Forge uses a
proprietary approach comprised of molecular modeling for rational
drug design along with fundamental knowledge and expertise in
bioinorganic chemistry to target metalloproteins. The
name Forge Therapeutics comes from two definitions for forge: to
manipulate (inhibit) a metal object (metalloprotein)
and to move forward steadily with a purpose (the Forge
team). Forge Therapeutics, Inc., maintains its
headquarters in San Diego,
California. To learn more please
visit www.ForgeTherapeutics.com.
Contact:
Info@ForgeTherapeutics.com
Logo - http://photos.prnewswire.com/prnh/20150807/256906LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/forge-therapeutics-announces-novel-antibiotic-presentation-at-the-american-society-of-microbiology-conference-on-antibacterial-development-300376235.html
SOURCE Forge Therapeutics, Inc.
